## Important information for the patient

VANFLYTA can cause an abnormal electrical activity in your heart called "prolonged QT interval" which may lead to a life-threatening disturbance of the heart rhythm. Your healthcare professional will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before you take VANFLYTA and while you are taking it.

## Contact your doctor immediately if:

- You are feeling dizzy, lightheaded, or faint.
- You sense a change in heart rhythm, for example, palpitations or an abnormality of your pulse. You may feel your heart is beating too fast, but you may also sense a more nonspecific or vague change.
- You have fainted or have been unconscious, even if it was only for a very short period of time, for example, seconds.
- You suffer from diarrhea or vomiting, or are unable to eat or drink fluids in sufficient amounts.
- You feel any other sudden change in your well-being.
- Your medicines are changed by a physician other than the prescribing physician for VANFLYTA.

Consult your doctor first before taking VANFLYTA with any other medicines, including medicines obtained without a prescription or supplements as these may increase the risk of you developing QT interval prolongation.

**For more information, please read the package leaflet.**

Find the full product monograph that is prepared for healthcare professionals and includes Patient Medication Information by visiting the Health Canada website: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html; the manufacturer's website www.daiichi-sankyo.ca, or by calling 1-866-791-9292.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

Daiichi-Sankyo

CA 122977

# PATIENT CARD
# VANFLYTA®
## quizartinib

- Please keep this card with you at all times.
- This card contains important safety information that you should know before you take VANFLYTA and during treatment with VANFLYTA.
- Show this card to any doctor, nurse, pharmacist or surgeon before any medical intervention or treatment.

Please detach this section here.

## Patient information

Patient name:

.....

Date of Birth: .....

In case of emergency, please contact:

Name: .....

Phone number:

.....

## Treatment information

(To be completed by physician or patient)

VANFLYTA has been prescribed at a once-daily dose of:

..... mg

Started on:

..... / ..... (mm/yy)

## Prescriber information

(To be completed by physician or patient)

For more information or in case of emergency, please contact:

Physician's name:

.....

Phone number:

.....

## Important information for healthcare professionals

VANFLYTA can prolong the QT interval. Torsades de pointes, cardiac arrest, and sudden death have been reported in patients receiving VANFLYTA.

- Reduce VANFLYTA dose if QTcF is >480 ms, interrupt VANFLYTA if QTcF is >500 ms, and permanently discontinue if associated with torsades de pointes, polymorphic ventricular tachycardia or signs/symptoms of life-threatening arrhythmia.
- During VANFLYTA treatment, monitor ECG and serum electrolytes; correct hypokalemia and hypomagnesemia.
- Avoid non-essential medicines that prolong the QT interval. If unavoidable, monitor ECG frequently.
- The dose of VANFLYTA should be reduced when used concomitantly with strong CYP3A4/5 inhibitors.

**For more information, please see the Product Monograph.**